Healthcare provider profile · identity verified

Edward Dennis Scanlan, MD

Internal Medicine · BRANDON, FL · NPI 1861475196

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	355	105
Levothyroxine Sodium	Levothyroxine Sodium	310	83
Lisinopril	Lisinopril	291	87
Amlodipine Besylate	Amlodipine Besylate	164	49
Metoprolol Succinate	Metoprolol Succinate	158	49
Rosuvastatin Calcium	Rosuvastatin Calcium	141	43
Losartan Potassium	Losartan Potassium	122	38
Metformin Hcl	Metformin Hcl	117	36
Pantoprazole Sodium	Pantoprazole Sodium	114	38
Alprazolam	Alprazolam	108	27
Olmesartan Medoxomil	Olmesartan Medoxomil	104	31
Simvastatin	Simvastatin	101	32
Omeprazole	Omeprazole	98	32
Clopidogrel	Clopidogrel Bisulfate	94	28
Tamsulosin Hcl	Tamsulosin Hcl	90	25
Metoprolol Tartrate	Metoprolol Tartrate	83	28
Hydrochlorothiazide	Hydrochlorothiazide	81	27
Gabapentin	Gabapentin	76	20
Trulicity	Dulaglutide	76	12
Meloxicam	Meloxicam	71	25
Pravastatin Sodium	Pravastatin Sodium	66	22
Fluticasone Propionate	Fluticasone Propionate	64	23
Allopurinol	Allopurinol	61	21
Escitalopram Oxalate	Escitalopram Oxalate	61	20
Albuterol Sulfate Hfa	Albuterol Sulfate	56	21
Furosemide	Furosemide	56	20
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	55	17
Jardiance	Empagliflozin	53	15
Potassium Chloride	Potassium Chloride	51	17
Carvedilol	Carvedilol	50	18
Tizanidine Hcl	Tizanidine Hcl	46	24
Trazodone Hcl	Trazodone Hcl	46	17
Chlorthalidone	Chlorthalidone	44	12
Montelukast Sodium	Montelukast Sodium	42	18
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	41	suppressed
Lovastatin	Lovastatin	39	12
Eliquis	Apixaban	38	suppressed
Finasteride	Finasteride	37	12
Zolpidem Tartrate	Zolpidem Tartrate	37	13
Atenolol	Atenolol	36	suppressed
Farxiga	Dapagliflozin Propanediol	35	suppressed
Donepezil Hcl	Donepezil Hcl	34	suppressed
Ezetimibe	Ezetimibe	33	12
Glipizide	Glipizide	33	11
Mirtazapine	Mirtazapine	33	11
Clonazepam	Clonazepam	32	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	32	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	32	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	31	suppressed
Benazepril Hcl	Benazepril Hcl	30	suppressed
Buspirone Hcl	Buspirone Hcl	30	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	30	suppressed
Lorazepam	Lorazepam	30	suppressed
Ozempic	Semaglutide	30	suppressed
Bupropion Xl	Bupropion Hcl	29	suppressed
Xarelto	Rivaroxaban	29	suppressed
Citalopram Hbr	Citalopram Hydrobromide	28	suppressed
Sertraline Hcl	Sertraline Hcl	28	suppressed
Valacyclovir	Valacyclovir Hcl	28	suppressed
Ipratropium Bromide	Ipratropium Bromide	27	14
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	26	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	26	suppressed
Spironolactone	Spironolactone	25	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	25	11
Azelastine Hcl	Azelastine Hcl	24	11
Fenofibrate	Fenofibrate	24	suppressed
Temazepam	Temazepam	24	suppressed
Duloxetine Hcl	Duloxetine Hcl	23	11
Hydroxyzine Hcl	Hydroxyzine Hcl	23	11
Verapamil Er	Verapamil Hcl	23	suppressed
Synthroid	Levothyroxine Sodium	22	suppressed
Metformin Hcl Er	Metformin Hcl	21	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	20	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	20	18
Propranolol Hcl	Propranolol Hcl	20	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	19	13
Glipizide Er	Glipizide	19	suppressed
Ketoconazole	Ketoconazole	19	suppressed
Propranolol Hcl Er	Propranolol Hcl	19	suppressed
Glimepiride	Glimepiride	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	suppressed
Edarbi	Azilsartan Medoxomil	17	suppressed
Liothyronine Sodium	Liothyronine Sodium	17	suppressed
Meclizine Hcl	Meclizine Hcl	17	suppressed
Prednisone	Prednisone	17	12
Acyclovir	Acyclovir	16	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	16	suppressed
Rizatriptan	Rizatriptan Benzoate	16	suppressed
Tresiba Flextouch U-200	Insulin Degludec	16	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	15	suppressed
Celecoxib	Celecoxib	15	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	15	suppressed
Diclofenac Sodium	Diclofenac Sodium	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Nifedipine Er	Nifedipine	15	suppressed
Ramipril	Ramipril	15	suppressed
Valsartan	Valsartan	15	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	14	suppressed
Ibuprofen	Ibuprofen	14	suppressed
Mounjaro	Tirzepatide	14	suppressed
Primidone	Primidone	14	suppressed
Sildenafil Citrate	Sildenafil Citrate	14	suppressed
Clonidine Hcl	Clonidine Hcl	13	suppressed
Baclofen	Baclofen	12	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	12	suppressed
Cefdinir	Cefdinir	12	12
Diazepam	Diazepam	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Gemfibrozil	Gemfibrozil	12	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Vascepa	Icosapent Ethyl	12	suppressed
Dutasteride	Dutasteride	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed
Testosterone Cypionate	Testosterone Cypionate	11	suppressed
Ventolin Hfa	Albuterol Sulfate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error